US: BRIBF - Brii Biosciences Limited

Rentabilité sur six mois: +7.57%
Rendement en dividendes: 0.00%

Calendrier des promotions Brii Biosciences Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Brii Biosciences Limited

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV.

plus de détails
It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.briibio.com
Цена ао 0.1346
Changement de prix par jour: +0.2972% (0.1346)
Changement de prix par semaine: +0.2972% (0.1346)
Changement de prix par mois: +0.2972% (0.1346)
Changement de prix sur 3 mois: +7.57% (0.1255)
Changement de prix sur six mois: +7.57% (0.1255)
Changement de prix par an: -41.28% (0.2299)
Evolution du prix sur 3 ans: -93.81% (2.18)
Evolution des prix depuis le début de l'année: +7.57% (0.1255)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -78.73 0
Rentabilité Ebitda, % -67.51 0
Rentabilité EPS, % -95.34 0
Total: 2
Plus de détails

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO 1964 (61 année)
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Secretary and Executive Director 1979 (46 années)
Dr. Eleanor de Groot Ph.D. Chief Technology Officer 1969 (56 années)
Dr. Brian Alvin Johns Ph.D. Chief Scientific Officer
Sarah Qiu Associate Director of Investor Relations
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of Human Resources 1976 (49 années)
Mr. Coy Stout Head of Patient Advocacy 1972 (53 année)
Dr. Lianhong Xu Ph.D. Head of Discovery 1967 (58 années)
Dr. Qing Zhu Ph.D. Head of China Research & Development 1968 (57 années)
Dr. David Margolis M.D., M.P.H. Chief Medical Officer 1975 (50 années)

Adresse: China, Beijing, Building 7 International Science Park - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.briibio.com